Computational methods will be developed and applied to design effective anti-HIV drugs. Monte Carlo (MC) statistical mechanics and Molecular dynamics (MD) simulations will be used to yield quantitative predictions on the structure, energetics, and ligand binding for HIV proteins. The current focus is on understanding and optimizing the activity of non-nucleotide inhibitors of HIV-1 reverse transcriptase (NNRTIs). The MCPRO software system will be used with the OPLS force fields in extensive studies of RT-ligand complexes. Specifically, (1) free-energy perturbations (FEP) and liner response (LRSA) calculations will be carried out for a series of 10-50 analogs of nevirapine and MKC-442 to seek correlations between the computed binding affinities and observed anti-HIV-1 activities. The calculations will be executed in parallel on a multiprocessor computer system. The unprecedentedly large database of results will elucidate the origins of binding variations for RT and also further refine and validate the methodology. (2) Resistance to nevirapine and MKC-442 will be examined through simulations of the effects of key mutations on the binding affinities and structures of the complexes with RT. The appropriate thermodynamic cycle also requires simulations that will provide structures of the unliganded mutant proteins, which have not yet been characterized by diffraction experiments. (3) These results will form a basis for the design of NNRTIs that can defeat the resistance-conferring mutations. Modifications of nevirapine and MKC-442 aimed particularly at the key Y181C mutation will be tested through FEP calculations on the binding of analogs to the native and mutant protein. New NNRTIs will also be developed and optimized through the novel extension of the computational approaches in a combinatorial manner.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI044616-01
Application #
2794704
Study Section
Special Emphasis Panel (ZRG5-AARR-3 (01))
Program Officer
Litterst, Charles L
Project Start
1999-01-01
Project End
2002-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Yale University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kudalkar, Shalley N; Beloor, Jagadish; Quijano, Elias et al. (2018) From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci U S A 115:E802-E811
Dodda, Leela S; Tirado-Rives, Julian; Jorgensen, William L (2018) Unbinding Dynamics of Non-Nucleoside Inhibitors from HIV-1 Reverse Transcriptase. J Phys Chem B :
Kudalkar, Shalley N; Beloor, Jagadish; Chan, Albert H et al. (2017) Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Mol Pharmacol 91:383-391
Chan, Albert H; Lee, Won-Gil; Spasov, Krasimir A et al. (2017) Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. Proc Natl Acad Sci U S A 114:9725-9730
Jorgensen, William L (2016) Computer-aided discovery of anti-HIV agents. Bioorg Med Chem 24:4768-4778
Lee, Won-Gil; Frey, Kathleen M; Gallardo-Macias, Ricardo et al. (2015) Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 25:4824-7
Frey, Kathleen M; Puleo, David E; Spasov, Krasimir A et al. (2015) Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J Med Chem 58:2737-45
Gray, William T; Frey, Kathleen M; Laskey, Sarah B et al. (2015) Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. ACS Med Chem Lett 6:1075-9
Mukerjee, Anindita; Iyidogan, Pinar; Castellanos-Gonzalez, Alejandro et al. (2015) A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium. Bioorg Med Chem Lett 25:2065-7
Cole, Daniel J; Tirado-Rives, Julian; Jorgensen, William L (2015) Molecular dynamics and Monte Carlo simulations for protein-ligand binding and inhibitor design. Biochim Biophys Acta 1850:966-971

Showing the most recent 10 out of 49 publications